Keyword
Quick search:
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Seagen's (SGEN) Tisotumab Vedotin BLA Gets FDA Priority Review
2 Genmab and Seagen's BLA for tisotumab vedotin accepted for priority re
3 BLA Submitted for F-627 to Treat Chemo-Induced Neutropenia in Breast Cancer
4 Provention Bio gives update on teplizumab BLA, FDA feedback
5 BLA! to Represent Mr. Men and Little Miss in EMEA
6 Kite submits supplemental BLA for Tecartus to treat advanced ALL
7 Guess Who's Behind the New Menu at Downtown's Bar Leather Apron
8 FDA accepts Genmab, Seagen's tisotumab vedotin BLA application for review
9 Provention Bio shares struggle after FDA feedback on teplizumab BLA, analyst downgrades
10 VERIFY: What's the difference between Emergency Use Authorization and FDA approval?
11 TG Therapeutics completes rolling submission of ublituximab combo BLA as leukemia treatment
12 France Ridesharing Market 2021 Global Insights and Business Scenario- Bla bla Car, goCarShare, Zify France, Flix Mobility, Carpool World, Mobicoop – KSU | The Sentinel Newspaper
13 Molecular epidemiology of mcr-1, blaKPC-2, and blaNDM-1 | IDR
14 Rolling BLA for Ublituximab and Umbralisib in CLL Completed for FDA Submission
15 Philippines: Intellectual Property Office amends rules on mediation
16 Tisotumab Vedotin Under Review for Recurrent or Metastatic Cervical Cancer
17 Balochistan: BLA claims responsibility for bomb blast in Hub
18 CTD reveals SRA links with BLA
19 Balochistan CTD busts BLA cell, two killed
20 Ramadan arrangements reviewed at Bla
21 Not in the office? The best cafes and restaurants to work from in Dubai
22 Alexis Morante launches into fiction in El universo de Óliver
23 Exclusive: Actor-Comedian Chris Tucker gives advice to young black golfers in Augusta
24 3 mega-venues opening in Dubai that you need on your radar
25 BLA claims Terror attack on Pakistan Army
26 DC Bla reviews implementation of PMAY Urban
27 TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting
28 MP Bla reviews implementation of CSSs, developmental projects
29 IBN ABDUR REHMAN (1930 — 2021)
30 There are 'definitely merits' to reparations, says the first Black Fed president
31 TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis
32 Journalist from Bla, bereaved
33 Transportation Aggregators Market In-depth Analysis, Competitive Landscape By 2026: Gett, Aritron, Beijing Xiaoju Keji Co., Ltd. (Didi Dache), Bla Bla Car, GrabTaxi Pte Ltd Block (Grab Taxi), Ola
34 Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
35 4 more trains to run between Bla-Budgam stations from April 1
36 National [WATCH] COVID-19 briefing: Two deaths and 27 new cases
37 FDA Allows for Omalizumab Self-Injection Across All Indications
38 FDA could delay decision on AstraZeneca COVID-19 vaccine
39 Jacqueline Jossa and Dan Osborne hit out at online trolls for talking about their kids
40 Agriculture Dept organizes Farmers Workshop/ Seminar at Bla
41 Toronto Maple Leafs Trade Deadline Live Updates: At least one more deal likely to come from Kyle Dubas
42 Furious Dan Osborne threatens to ‘punch trolls heads in’ as Jacqueline Jossa claims abuse of kids is mak...
43 Transportation Aggregators Market Report 2021: COVID-19, Qualitative Analysis a
44 CytoDyn Executes Exclusive Supply and Distribution Agreement with Chiral Pharma Corporation to Provide Up to 200,000 vials of Leronlimab to Philippines
45 argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
46 BrainStorm Receives Feedback on Potential BLA Submission for ALS Therapy
47 Janssen Files Rolling BLA Submission for on Cilta-Cel in R/R Multiple Myeloma
48 Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
49 FDA Grants Priority Review to BLA for Retifanlimab as Possible Treatment for SCAC
50 Adcom gives thumbs up for islet therapy that may not have much market
51 Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
52 Toripalimab Rolling Submission of BLA Initiated for Nasopharyngeal Carcinoma
53 FDA Accepts Bio-Thera’s BLA for Bevacizumab Biosimilar
54 Seagen (SGEN) Submits BLA to FDA for Cervical Cancer Drug
55 Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer
56 FDA to Review BLA for Merck's Novel 15-Valent Pneumococcal Conjugate Vaccine
57 Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(plasminogen) BLA
58 BLA Submission Delayed for Balstilimab For Treatment of Recurrent/metastatic Cervical Cancer
59 FDA Grants Priority Review to BLA for Vicineum for Treatment of High-Risk, BCG-Unresponsive NMIBC
60 Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
61 Outlook Therapeutics' Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission
62 VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine
63 Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
64 Pandemic travel restrictions force FDA to delay a BLA review — involving a site inspection in Korea
65 BCLI: Awaiting BrainStorm’s Decision on NurOwn® BLA Filing…
66 FDA Accepts BLA for bluebird and BMS' Multiple Myeloma CAR-T Treatment
67 FDA Receives BLA for Lonca in Relapsed/Refractory Diffuse Large B-cell Lymphoma
68 Janssen Submits BLA for Amivantamab to Treat Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
69 FDA Accepts Biogen’s BLA for Alzheimer’s Candidate Aducanumab
70 FDA Accepts BLA for Biogen's Alzheimer's Drug, Grants Priority Review
71 What We're Reading: Public Transit Mask Mandate; BLA Decision on Alzheimer Drug Extended; Drug Pricing Rule Delayed
72 FDA Accepts BLA for Bevacizumab Biosimilar in Solid Tumors and Sets Action Date
73 Health Canada Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy
74 Provention Bio Announces US FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
75 Turning COVID-19 Vaccine EUA Into A BLA Will Require Six Months Of Additional Data
76 Manufacturers submit rolling BLA to FDA for CAR-T to treat advanced multiple myeloma
77 Immunocore to Submit BLA for Tebentafusp in Uveal Melanoma This Year
78 Sesen Bio Submits Completed Biologics License Application to the FDA for Vicineum™ and Has Requested Priority Review
79 U.K. MHRA Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy
80 FDA Will Not Complete Review of BLA for Lisocabtagene Maraleucel By PDUFA Date
81 Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma
82 FDA Defers Action on BLA for Bevacizumab Biosimilar MYL-1402O
83 Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed
84 TG Therapeutics Initiates BLA for Ublituximab Combo to Treat CLL
85 FDA Issues CRL for Ropeginterferon alfa-2b-njft BLA in PV
86 Formycon confirms BLA-Submission Strategy and Timeline for its Lucentis(R)* Biosimilar-Candidate FYB
87 Bla bla bla for biodiversity
88 Bluebird: delays push sickle cell therapy BLA back
89 Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon™ hGH for Pediatric Growth Hormone Deficiency (GHD)
90 FDA Postpones Review of BLA for Liso-Cel in R/R Large B-Cell Lymphoma
91 Pfizer (PFE) Pneumococcal Vaccine BLA Gets FDA's Priority Tag
92 BLA Submitted to FDA for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
93 DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years
94 Pogba pledges Man United loyalty after Raiola comments
95 Liso-Cel BLA for Relapsed/Refractory LBCL Remains Under FDA Review
96 BLA Initiated for JZP-458 in Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
97 Iovance plant on track for 2022
98 FDA Defers BLA Action of Bevacizumab Biosimilar Due to COVID-19 Restrictions
99 CSLA Announces the 2021 Awards of Excellence Recipients
100 BioThera BLA for Roche Avastin biosimilar accepted by FDA